ischemia post-stroke depression
Conditions
Interventions
Non depressive group:Routine stroke treatment, once a day, 6 weeks
drug treatment group:Sertraline 50mg/day,6 weeks
Extracorporeal counterpulsation therapy group:Extracorporeal counterpulsation therapy, 30 minutes/time, 2 times/day, 6 weeks
Sponsors
Yuan Jiang
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? First time of stroke, meeting the diagnostic criteria for ischemic stroke, and confirmed by brain CT or MRI examination after onset; ? meets the diagnostic criteria for depression mentioned above; Stroke is the direct cause of depression; Ischemic stroke complicated with depression within 3 months of start; ? Stable vital signs, stable condition, and clear consciousness; ? 8 points = HAMD = 24 points; ? Age range from 18 to 80 years old; ? Clear awareness and ability to cooperate with Q&A; ? Volunteer to join this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: ? Individuals with a history of depression and other mental illnesses or a genetic history of familial mental illness, or those who have received antidepressant treatment before and after the onset of the disease; ? Progressive exacerbation of the condition, unstable vital signs, disturbance of consciousness or combined severe cardiopulmonary, liver and kidney dysfunction, and poor overall condition; ? Accompanied with vascular dementia and severe aphasia; ? Severe depression (HAMD = 25 points) or suicidal tendencies; ? Infectious diseases; ? Contraindications to external counterpulsation: moderate to severe aortic valve regurgitation; Dissecting aneurysm; Significant pulmonary arterial hypertension; Various hemorrhagic diseases or bleeding tendencies, or the use of anticoagulants, with an INR greater than 2.0; Valve disease, congenital heart disease, cardiomyopathy; Active phlebitis and venous thrombosis; Infected areas in the limbs during counterpulsation; Uncontrolled hypertension and arrhythmia; Severe left heart failure; Pregnancy, etc.; ? Those with Guillain Barre syndrome, Parkinson's disease, multiple sclerosis, multiple system atrophy, and motor neuron disease that affect SSR detection results; ? Not willing to sign an informed consent form, or the patient's compliance is poor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale ;Serum TNF- a;Serum BDNF;Serum VEGF; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sympathetic skin response test;Modified barthel index;Plasma Hcy;Serum hs-CRP; | — |
Countries
China
Contacts
Public ContactJiaojiao Wang
The First Affiliated Hospital of Chengdu Medical College
Outcome results
None listed